Kelly Gold Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold acquired 6,551 shares of the stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $1.65 per share, for a total transaction of $10,809.15. Following the purchase, the chief financial officer directly owned 74,428 shares in the company, valued at approximately $122,806.20. This trade represents a 9.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

CAMP4 Therapeutics Trading Up 12.2%

CAMP opened at $4.50 on Friday. The company’s 50 day moving average is $4.02 and its 200 day moving average is $4.31. The company has a market cap of $233.69 million, a price-to-earnings ratio of -1.91 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 12-month low of $1.32 and a 12-month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The business had revenue of $1.29 million for the quarter. As a group, analysts predict that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on CAMP. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.36.

Key CAMP4 Therapeutics News

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: CMP-002 is advancing into human trials. CAMP4 received regulatory clearance in Australia and Argentina to begin a Phase 1/2 study of CMP-002, an antisense oligonucleotide therapy for SYNGAP1-related disorders. The double-blind, placebo-controlled trial is expected to enroll at least 30 children ages 2 to 18. This is a significant milestone because SYNGAP1-related disorder has no approved disease-modifying treatments. CAMP4 advances SYNGAP1 treatment into human trials
• Positive Sentiment: Insider buying may signal management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively bought 36,031 shares at an average price of $1.65. While the purchases were modest in dollar value, they increased the insiders’ ownership positions and may be viewed positively by investors. CAMP4 insider purchase filing
• Positive Sentiment: Recent financing improves development funding. CAMP4 raised approximately $50.1 million in the second closing of a private placement. The proceeds are intended to support CMP-002 and the company’s early-stage pipeline, with participation from institutional investors including Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Negative Sentiment: The capital raise is significantly dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at about $1.53 per share-equivalent. The expanded potential share count and discounted issuance could limit per-share upside despite extending the company’s cash runway.
• Neutral Sentiment: Clinical risk remains high. CMP-002’s move into a Phase 1/2 trial is encouraging, but the therapy is still investigational. Safety and efficacy results in humans could differ materially from preclinical findings, making future trial updates key catalysts for CAMP.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bridgeway Capital Management LLC bought a new position in CAMP4 Therapeutics in the 2nd quarter worth $36,000. China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $61,000. Jefferies Financial Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at about $70,000. Bank of America Corp DE purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at about $86,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of CAMP4 Therapeutics in the fourth quarter worth about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.